Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting

Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patientsTranslational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md., Dec. 03, 2018 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ:...